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Background: Asthma is the most common chronic disease in childhood, characterized by chronic airway
inflammation. There are problems with the diagnosis of asthma in young children since the majority of the children
with recurrent asthma-like symptoms is symptom free at 6 years, and does not have asthma. With the
conventional diagnostic tools it is not possible to differentiate between preschool children with transient
symptoms and children with asthma. The analysis of biomarkers of airway inflammation in exhaled breath is a non-
invasive and promising technique to diagnose asthma and monitor inflammation in young children. Moreover,
relatively new lung function tests (airway resistance using the interrupter technique) have become available for
young children. The primary objective of the ADEM study (Asthma DEtection and Monitoring study), is to develop
a non-invasive instrument for an early asthma diagnosis in young children, using exhaled inflammatory markers
and early lung function measurements. In addition, aetiological factors, including gene polymorphisms and gene
expression profiles, in relation to the development of asthma are studied.
Methods/design:  A prospective case-control study is started in 200 children with recurrent respiratory
symptoms and 50 control subjects without respiratory symptoms. At 6 years, a definite diagnosis of asthma is
made (primary outcome measure) on basis of lung function assessments and current respiratory symptoms
('golden standard'). From inclusion until the definite asthma diagnosis, repeated measurements of lung function
tests and inflammatory markers in exhaled breath (condensate), blood and faeces are performed. The study is
registered and ethically approved.
Discussion: This article describes the study protocol of the ADEM study. The new diagnostic techniques applied
in this study could make an early diagnosis of asthma possible. An early and reliable asthma diagnosis at 2–3 years
will have consequences for the management of the large group of young children with asthma-like symptoms. It
will avoid both over-treatment of children with transient wheeze and under-treatment of children with asthma.
This might have a beneficial influence on the prognosis of asthma in these young children. Besides, insight into the
pathophysiology and aetiology of asthma will be obtained.
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Background
Asthma is one of the major chronic health problems in
children. Worldwide, approximately 40% of all young
children have at least one episode of asthmatic symptoms
like wheezing, coughing, and dyspnoea [1,2]. Although
asthmatic symptoms are common in preschool children,
only 30% will have asthma at the age of 6 years and over.
The rest of the children with recurrent respiratory symp-
toms is symptom-free at 6 years and does not has asthma
but transient, viral associated wheeze [1,3,4]. A reliable
diagnosis of asthma in young children is difficult. With
the conventional diagnostic measures it is currently not
possible to discriminate between "true asthma" in pre-
school children and children with "transient wheezing" in
association with frequent viral infections. An early asthma
diagnosis is important for the proper treatment of young
children with respiratory symptoms. An effective therapy
of asthma by means of anti-inflammatory treatment with
inhaled corticosteroids (ICS) is available. This treatment
has a beneficial influence on airway inflammation, respi-
ratory symptoms, asthma exacerbations, quality of life,
and lung function [5]. Probably, ICS are not very effective
in children with transient wheezing which may cause
unnecessary treatment with preventable costs and side-
effects [6,7]. Therefore, an early diagnosis will prevent
under-treatment of true asthmatics and over-treatment of
transient wheezers, and will improve asthma control.
Measuring inflammation
Although chronic airway inflammation is the most com-
mon feature in asthma, measurement of inflammation
plays a small role in the diagnosis and monitoring of
asthma. Currently, the 'golden standard' to measure air-
way inflammation is bronchoscopy with biopsy and/or
bronchoaleolar lavage. However, this is far too invasive
for normal routine use in (young) children. Since a non-
invasive method to measure inflammation is lacking,
diagnosis and management of asthma in young children
are currently based on subjective clinical features and
medical examination. Therefore, there is a lot of interest in
non-invasive techniques to assess inflammation, espe-
cially in children.
Inflammatory biomarkers in exhaled breath (condensate)
The last decade, non-invasive techniques are developed to
assess inflammation in the airways. One of these new
techniques is assessment of inflammatory biomarkers in
exhaled breath. This technique is currently possible in
young children, and is promising for an early asthma
diagnosis and monitoring of the disease [8-10]. The most
studied marker in exhaled breath is nitric oxide (NO). Ele-
vated levels of fractional exhaled NO (FeNO) are found in
both adults and children with asthma, as a consequence
of up regulation of the enzyme iNOS [9]. In addition to
FeNO, other gases can be measured in exhaled breath
including volatile organic compounds (VOCs). Inflam-
mation in the airways gives rise to reactive oxygen species
(ROS) which can degradate cell membranes through per-
oxidation of lipids [11,12]. Due to degradation of cell
membranes, volatile organic compounds, such as alkanes,
alkane derivates, and aldehydes, are formed. Increased
levels of alkanes (such as ethane and pentane), and alde-
hydes are described in exhaled breath during (exacerba-
tions of) asthma [13-15].
Besides gases in exhaled breath, non-volatile compounds
in exhaled breath condensate (EBC) can be measured in
children [10,16-19]. EBC is collected by cooling exhaled
breath in a condenser. During this non-invasive proce-
dure, small droplets of breath condensate are formed.
Besides water vapour, droplets consist of aerosol particles
that are released from the epithelial lining fluid of the air-
ways. They contain non-volatile inflammatory markers,
and there is evidence that abnormalities in condensate
composition reflect biochemical changes of the epithelial
lining fluid [20]. In EBC, inflammatory markers, such as
cytokines, chemokines and adhesion molecules, can be
measured. Increased concentrations of various markers in
EBC were found in patients with asthma [10,16-18,21].
Early lung function measurements
In the past 10 years new lung function techniques became
available in young children. Techniques to evaluate air-
way resistance like the interrupter technique (MicroRint),
impulse oscillation, and forced oscillation technique are
increasingly applied in young children [22-24]. In con-
trast to the forced expiration manoeuvres, these measure-
ments are performed during tidal breathing. The
measurements are possible in children of 1–2 years and
over. However, feasibility increases with age [22]. These
techniques are used in children with asthma to assess
baseline airway resistance, reversibility on bronchodila-
tors, bronchial hyperresponsiveness, and responses to
ICS.
Response to inhaled corticosteroid treatment
A good responsiveness to ICS is a hallmark of asthma
[25]. This response might discriminate between asthmatic
and non-asthmatic children. Several international guide-
lines advocate a trial of ICS in preschool children with
recurrent wheeze. However, the diagnostic value of the
response to ICS for asthma is not clear in these children.
Regulatory T-cells
The inflammatory response in asthma is highly complex
in which many inflammatory cells are involved. T-helper
(Th) cells play a central role in the inflammatory response
in asthma, and can be roughly divided in the pro-inflam-
matory Th2 cells and anti-inflammatory Th1 cells [26-29].
Regulatory T cells (Treg cells) inhibit both Th1 and Th2
cells which results in a balance of the immune system. An
imbalance between Th2 and Th1 cells occurs in asthmaBMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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with an increase of Th2, and a decrease of Th1 cells
[26,27]. This imbalance might be due to a decrease in
amount or function of Treg cells [28,29].
Genetic background
Asthma has a multifactorial aetiology in which genetic
factors, environmental influences, and their interaction
play an important role. Over the last two decades the
genetic background of asthma has become increasingly
clear through twin studies, and studies in subjects with a
family history of atopy and asthma. Around 30 to 100
genes are involved in asthma [30,31]. Although a lot of
progress has been made in the field of asthma genetics,
the influence of many candidate genes in relation to
asthma susceptibility in young children needs to be fur-
ther defined. Gene polymorphism in the coding
sequences of genes may affect the function of a protein.
Polymorphisms in the regulatory and promoter sequences
of genes may influence the expression characteristics of a
gene, making gene expression profiling an important area
in asthma research. Linking specific genetic polymor-
phisms and gene expression profiles to wheezing pheno-
types in children and to inflammatory levels in EBC and
lung function indices, leads to a better understanding of
early pathogenesis of asthma in young children (figure 1).
Subsequently, this will identify children with enhanced
risk.
Environmental factors in relation with asthma
The hygiene hypothesis suggests a relation between expo-
sure to microbes in early childhood and the development
of allergies and asthma. According to this hypothesis,
infections protect against asthma [32,33]. However, this is
not in line with increasing evidence that certain infections
might also promote asthma development [33]. A unifying
concept is still lacking, and the precise relationship
between infections and the development of asthma is not
clear.
Hypothesis
The primary hypothesis of the ADEM study (Asthma
DEtection and Monitoring study), is that an early asthma
diagnosis is possible using non-invasive measurements of
biomarkers of airway inflammation and oxidative stress
in exhaled breath (condensate), and early lung function
measurements (airway resistance). Besides, this study tests
the hypothesis that certain gene polymorphisms and gene
Relation between genetic background and pathophysiology in asthma Figure 1
Relation between genetic background and pathophysiology in asthma. Central features in the pathophysiology of 
asthma are chronic airway inflammation and airway (hyper)responsiveness. These features can be measured by markers in 
exhaled breath condensate and MicroRint, respectively, and are influenced by genetic factors.BMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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expression profiles, early infections, and Treg cells in blood
are related to the development of asthma.
Aim and research questions
The primary aim of the study is to develop a non-invasive
instrument for an early asthma diagnosis in young chil-
dren. Besides, aetiological factors (such as Treg cells, gene
polymorphisms, gene expression profiles and infections
at early age) are studied in relation to the early develop-
ment of asthma. This second part of the study has an
explorative character.
The primary research question is
Which non-invasive inflammatory biomarkers in exhaled
breath (condensate) or early lung function indices (base-
line airway resistance, response after a bronchodilator)
can reliably predict asthma at an early age?
The secondary research questions are
1) What are the differences in inflammatory biomarkers
and lung function indices between asthmatic and non-
asthmatic children?
2) Which of the selected gene polymorphism and/or gene
expression profiles are related to asthma susceptibility in
young children?
3) Is early colonisation of the airways and intestines
related to the development of asthma?
4) What are the differences in amount of Treg cells between
asthmatic and non-asthmatic children?
5) What is the relation between gene coding and gene
expression of inflammatory markers (e.g. genes coding for
IL-4, sICAM, IL-13, TNF-, and ADAM-33), levels of
inflammatory markers in EBC, and lung function indices
during the development of asthma in young children?
To answer these research questions, markers in different
media are measured (table 1).
Methods/Design
Study design
The study design is a long-term prospective case-control
study during 4 years. The study consists of four phases: 1)
the selection phase; 2) the early diagnosis phase; 3) the
follow-up phase; and 4) the definite diagnosis at 6 years
(figure 2).
In the selection phase, a random sample of children aged 2–
3 years of primary care practice and of two cities in Lim-
burg, the Netherlands, receives a standardised question-
Table 1: Overview of measurements per visit
Media/method ED I ED II ED III Follow- up Definite diagnosis
Exhaled breath Nitric Oxide ●● ● ● ●
Volatile organic compounds ●● ● ● ●
Exhaled breath condensate Cytokines 
(IL1a,-2,-4,-5,-6,-10,- 12p70,-13,-18, IFNg, TNFa)
●● ● ● ●
Chemokines 
(MIP1a, MIF, eotaxin, RANTES, IL8, MCP1)
●● ● ● ●
Adhesion molecules (sICAM) ●● ● ● ●
Nitrate/nitrite ●● ● ● ●
Blood White blood cell count, differentiation, number of 
eosinophils
●
Total Immunoglobulin E (IgE), and specific IgE ●●
Regulatory T cells ●
Gene polymorphism 
(e.g. in IL-4, IL-13, TNF-alpha, ADAM33)
●
Gene expression (e.g. in IL-4, IL-13, TNF-alpha) ●
Anti bodies against Mycoplasma en Chlamydia 
pneumoniae
●
Saliva Colonisation of Pneumococcen, Haemophilus 
(para)influenza, Staphylococcus aureus
●●
Faeces Colonisation of E.Coli en Clostridium difficile ●
Lung function test Airway resistance (MicroRint) before and after 
bronchodilator
●● ● ●
Dynamic spirometry (MEFV, FEV1, FVC, MEF50) before 
and after bronchodilator
●
Histamine provocation test ●
Questionnaire Parental administrated respiratory symptoms (ISAAC) ●● ● ● ●
Demographic factors (e.g. smoking, pets) ●● ● ● ●
Parental administrated Quality of life (FSII) ●● ● ● ●
ED I/II/III = Consecutive measurements in early diagnosis phaseBMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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naire on respiratory symptoms (ISAAC) [34]. From the
results of this questionnaire, a group of 200 children with
recurrent asthma-like symptoms (experimental group),
and 50 children with no respiratory symptoms (control
group) are selected. In the early diagnosis phase, a two-
month trial with ICS is performed. In addition, repeated
measurements of early predictors, like exhaled biomark-
ers of inflammation/oxidative stress, and lung function
tests are assessed. During the follow-up phase, the develop-
ment of respiratory symptoms, lung function indices, and
inflammatory biomarkers are studied. At six years of age,
a definite diagnosis of asthma is made, based on various
lung function measurements and current respiratory
symptoms ('golden standard'). At this stage, early meas-
urements of (non-invasive) inflammatory biomarkers
and lung function measurements are related to the final
diagnosis of asthma in order to select the combination of
biomarkers which can assess asthma reliably. The study
design is described in more detail below.
Selection phase
Subjects are recruited from two sources. The first source
consists of general practices from the Registration Net-
work of Family Practices of the University of Maastricht.
This department is used for other studies and has exten-
sive research logistics, including 55 general practitioners
and 110,000 patients [35]. In addition, a community-
based random sample of children aged 2–3 is selected of
two cities in Limburg (Maastricht and Heerlen).
Parents receive information about the study, along with
the informed consent form. When parents are willing to
participate with their child in the study, they are asked to
fill in an internationally standardised questionnaire on
respiratory symptoms (ISAAC) [34]. From the results of
the ISAAC questionnaire, 200 children with recurrent res-
piratory symptoms (experimental group) and 50 with no
respiratory symptoms (control group) are selected.
Experimental group
In total, 200 children aged 2–3 years old with recurrent
respiratory symptoms participate in the experimental
group. The inclusion criterion for this group is that chil-
dren experienced at least 2–3 episodes of wheeze during
their life, based on the parents-completed ISAAC ques-
tionnaire. Exclusion criteria are mental retardation, car-
diac anomalies, congenital malformations, other diseases
of the lungs/airways, Crohn's disease or rheumatic arthri-
tis, and the inability to perform lung function measure-
ments or exhaled breath collection. The use of ICS is not
an exclusion criterion. However, ICS are stopped at least
four weeks before the start of each measurement.
Control group
In addition, 50 children aged 2–3 years without wheeze
and other recurrent respiratory symptoms are selected,
based on the parents-completed ISAAC questionnaire.
Exclusion criteria are similar as for the experimental
group.
After written informed consent, children and parents are
invited for a visit to the lung function laboratory. The lung
function assistant and/or research physician further eval-
uates suitability for participation. A questionnaire on
demographic data, medical history of the child, family
history, day-care attendance, housing, prescribed drug
therapy, exposure to pets, and passive smoking is com-
pleted.
Early diagnosis phase
In the early diagnosis phase, repeated measurements of
early predictors, including lung function tests and markers
of inflammation/oxidative stress in exhaled breath (con-
densate), blood and faeces are performed in both experi-
mental and control group (table 1). Besides, a controlled
cross-over trial with ICS is part of the diagnosis phase for
the children in the experimental group. This trial consists
of a treatment period of two months with ICS therapy
(Beclametasone extra fine two times 100 microgram a day
via the Aerochamber®), and a two-month period without
ICS. Based on randomisation, half the children start with
ICS, the other half starts the period without ICS. All other
anti-inflammatory medication is stopped. Clinical visits
and measurements for the ICS trial occur at 0, 2, and 4
months.
Follow-up phase
The purpose of the third phase is to monitor development
of respiratory symptoms, inflammatory biomarkers, and
lung function in both the experimental and control group.
At 12-month intervals, each child visits the lung function
laboratory for measurements of inflammatory biomarkers
and lung function tests. All relevant therapy (e.g. dose and
period) is registered. If possible, ICS are stopped four
weeks before the measurements. In practices of the partic-
ipating general practitioners, a computer program for the
study is installed. With this program, general practitioners
register standardised diagnoses of asthma, atopic dermati-
tis and allergic rhinoconjunctivitis on-line. Diagnoses are
based on international Classification of Health Problems
in Primary Care (ICHPPC) definitions.
Children are treated according to the guidelines for treat-
ment of asthma of the Dutch Society of General Practice
[36]. These national guidelines approach the interna-
tional GINA guidelines of asthma diagnosis and treat-
ment [25].
Definite asthma diagnosis phase
At six years, a definite diagnosis of asthma is made (pri-
mary outcome measure and 'golden standard') upon the
presence of current asthma symptoms in combinationBMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
Page 6 of 12
(page number not for citation purposes)
Study design Figure 2
Study design. ED I/II/III = Consecutive measurements in Early Diagnosis phase; ICS = Inhalation corticosteroids.BMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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with characteristic lung function abnormalities (reversi-
bility on a beta-2 agonist and/or bronchial hyperrespon-
siveness).
Airway reversibility is defined as an increase in FEV1 of 
9% after 400 microgram of extra fine salbutamol. Bron-
chial hyperresponsiveness is present when a 20% fall in
FEV1 is obtained with a provocative concentration of his-
tamine (PC20) of 8 mg/ml or less. Early measurements of
(non-invasive) inflammatory biomarkers and lung func-
tion measurements are related to the final diagnosis of
asthma. The definite diagnosis of asthma divides the chil-
dren in the experimental group into an 'asthma group'
and a 'transient wheeze group'.
Study parameters
As described before, repeated measurements are per-
formed from inclusion until the asthma diagnosis. One
hour before each experiment, eating and exercise are not
allowed. The parameters that are measured are listed
below (table 1).
Fractional exhaled Nitric Oxide in exhaled breath
FeNO in exhaled breath is offline collected in a 500 ml
inert balloon during tidal breathing. Exhaled breath is col-
lected via a face mask that is connected to a two-way non-
rebreathing valve [37]. The valve allows inspiration of
NO-free air from a NO-inert reservoir to avoid contamina-
tion by ambient NO. To avoid nasal contamination a sep-
tum between nose and mouth is placed in the mask. After
a washout period of five tidal breaths, an NO-inert bag is
connected on the expiratory port of the valve to collect
exhaled breath. FeNO levels in the bag are determined by
offline sampling using the NIOX® (Aerocrine, Solna, Swe-
den).
Chromatogram of exhaled breath
During tidal breathing, expired air is collected in a 1-litre
inert bag by means of the 2-way valve system described
above. After collection, the bag is immediately emptied
across a small tube with active carbon, with rapid adsorp-
tion and stabilisation of volatile markers. A profile of
inflammatory biomarkers in exhaled breath is assessed by
means of gas chromatography time-of-flight mass spec-
trometer (GC-TOF-MS) [38].
Inflammatory markers in exhaled breath condensate
To collect EBC in young children a special system is
designed in close collaboration with the Department of
Instrument Development Engineering & Evaluation of the
MUMC [19]. Figure 3 shows a schematic representation of
this closed glass condenser. In short, children breathe tid-
ally for ten minutes through a mask connected to the two-
way non-rebreathing valve. EBC is collected using a
cooled double-jacketed glass condenser that is connected
to the valve via a tube. The two-way valve and tubing serve
as a trap to minimize salivary contamination. Circulating
ice water cools the condenser to 0°C. During this proce-
dure small droplets of breath condensate are formed
which is collected in a tube. During the procedure, chil-
dren can watch cartoons. Exhaled breath that does not
directly condensate in the condenser is collected in an
inert bag that is connected to the condenser. To avoid that
the exhaled breath condensates in the bag, the bag is
placed in a heated box (37°C). When the child finished
the procedure, the exhaled breath that is temporarily col-
lected in the inert bag is conducted through the condenser
(recirculation) to increase the amount of condensate.
After collection, EBC is rapidly frozen at -80°C using dry
ice and is stored at -80°C until analysis. Inflammatory
markers (e.g. IFN-gamma, TNF-alpha, Interleukins,
sICAM) are assayed by the Luminex®  technology
(Luminex Corporation, Austin, TX, USA) [39].
Polymorphism in inflammatory genes
Saliva is used for DNA collection. DNA is isolated accord-
ing to the protocol of Oragene (Oragene, Ottowa, Can-
ada). For genotyping matrix-assisted laser desorption/
ionization-time of flight (MALDI-TOF) mass spectrome-
try is used (Sequenom Inc., San Diego, USA). Sequences
are evaluated in the ProxSNP and PreXTEND software
http://www.realsnp.com. The reactions are designed using
Sequenom Assay Designer 3.1 software. Genotyping is
executed according to the iPLEX method. In short, multi-
plexed polymerase chain reaction (PCR) is performed in 5
ul volume using the Sequenom PCR kit. Deactivation of
unincorporated deoxyribonucleotide triphosphates
(dNTPs) is achieved using shrimp alkaline phosphatase.
The iPLEX reagent kit carries out primer extension. To
remove residual salt from the reactions a cation exchange
resin is added. Approximately 15 nl of the primer exten-
sion reaction are loaded onto a matrix pad of a Spectro-
CHIP (Sequenom). MassARRAY Compact Analyzer is
used to analyse the SpectroCHIPs (Sequenom). The PCR
primer and extension primer sequences are available on
request. The genotyping calls are made using Typer Ana-
lyzer 4.0 software. The SNP's that are studied are selected
from Pubmed in combination with the HapMap database
http://www.hapmap.org. Inclusion of genes for SNP's
analysis is based on the following criteria: association
with asthma based on biomedical literature, a functional
difference between the variant allele and the wild-type
allele and a minor allele frequency of at least 5% in the
(asthmatic) population. Genes selected for analysis are:
Fillagrine, IL-4, IL-10, IL-13, TNF-alpha, sICAM,
ADAM33, Toll-like receptors and ORMDL3.
Venous blood sampling
At the first visit of the study, venous blood is sampled for:BMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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1. White blood cell count, differentiation, number of
eosinophils;
2. Total Immunoglobulin E (IgE) and specific IgE for
pollen, cats, dogs, house dust mite, Aspergillus Fumi-
gatus (Pharmacia, Uppsala, Sweden);
3. Presence of Treg cells (described below);
4. Gene-expression profiles of relevant markers
(described below);
5. Infection serology (Mycoplasma, Chlamydia).
In addition, total and specific IgE are also determined at
the last visit.
Regulatory T-cells
Treg cells were quantified in the circulation by flow cytom-
etry. The phenotype of the Treg was defined as being posi-
tive for CD3, CD4, and CD25 (IL-2R), while being
negative for CD127 (IL-7R). Cells with this phenotype
have been shown to be positive for FoxP3 [40], a tran-
Schematic representation of the glass closed condenser Figure 3
Schematic representation of the glass closed condenser. 1. Inclined glass condenser with a moveable plunger. 2. Swan-
neck tubing (saliva trap) and two-way non-rebreathing valve, connected to a face mask with separated nose and mouth cavity. 
3. Entrance of inspired room air. 4. Cooling unit. 5. Sample vial to collect EBC. 6. Ventilator system for recirculation of non-
condensed exhaled breath. 7. Heated (at 37°C) inert Tedlar™ gas sample bag to collect the residual non-condensed exhaled 
breath.BMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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scription factor which is closely related to the suppressive
function of Treg.
Gene expression of markers of inflammation
In addition to gene polymorphisms, gene expression
markers of inflammation are determined in the early diag-
nosis phase of the study. Total RNA from venous blood is
isolated that is used to generate cDNAs by poly-A and ran-
dom priming reverse transcription. The cDNAs are stored
and used for the production of copy RNAs pools that can
be used to hybridize to custom made arrays of genes.
Hybridization of the arrays enables us to select genes with
an up- or down-regulated expression in children with
asthma. The array hybridization is used only as a primary
indicator and the results are validated by real-time quan-
titative PCR. Inclusion of genes for gene expression is
based on the same criteria as the inclusion of genes for
SNP's analysis and on an altered gene expression in
asthma suggested in the literature. Genes studied are the
same genes as for polymorphisms (described above). In
addition eotaxin, RANTES, MIF, MIP1alpha, GST, heme
oxygenase, catalase, superoxide dismutase, NOS1, STAT6,
NF-kappa B, chitinase and keratins are studied.
Infection serology
At the start and at the end of the study, a nose- and throat
swab is collected to analyse possible colonisations of
Pneumococcen, Haemophilus (para) influenzae, and Sta-
phylococcus aureus. At the first visit, antibodies of
Chlamydia and Mycoplasma pneumoniae are analysed in
venous blood, using ELISA. In addition, faeces are tested
for E. coli and Clostridium difficile.
Lung function tests of airway resistance
Measurements of airway resistance are performed by
means of the MicroRint (Micro Medical, Rochester Ltd,
UK) [22]. While children are sitting in an upright posi-
tion, they are asked to breathe tidally through a facemask.
Seven airflow interruptions are made on the peak flow of
expiration. The median MicroRint value together with the
flow and pressure curves are displayed. The median
MicroRint value of at least five successful interruptions is
used for analysis. Thereafter, 300 microgram of extra fine
salbutamol is inhaled via the Aerochamber®. After 15 min-
utes, MicroRint measurements are repeated to assess the
reversibility to a beta-2 agonist.
Dynamic spirometry, bronchial hyperresponsiveness and reversibility
At the end of the study, additional lung function tests are
performed like described before [35]. Maximal expiratory
flow volume curves (MEFV) curves are assessed in each
child by means of the Flowscreen® (Jaeger, Wuerzburg,
Germany). The highest forced expiratory volume in one
second (FEV1), forced vital capacity (FVC), and maximal
expiratory flow at 50% FVC (MEF50) of three technically
satisfactory MEFV curves is used for analysis. After three
baseline MEFV curves, an aerosol of buffered saline is
inhaled, followed by aerosols of histamine acid phos-
phate in doubling concentrations from 0.03 to 16 mg/ml
at five minute intervals. Dynamic spirometry is repeated
once after 30, and after 90 seconds following each inhala-
tion. The inhalations of histamine are discontinued in
case of a 20% fall in FEV1 (PC20) or when 8 mg/ml hista-
mine has been administered. Thereafter, 400 microgram
of extra fine salbutamol is inhaled. After 15 minutes, three
MEFV curves are assessed in a comparable way. The
change in FEV1 is expressed as a percentage of the pre-
dicted value.
Questionnaires on respiratory symptoms and quality of life
Presence of cough, breathlessness, and wheezing are regis-
tered according to the internationally standardised ISAAC
questionnaire [34]. Besides, a questionnaire designed for
preschool children to record patterns of wheeze and other
respiratory symptoms is completed by parents [41]. In
addition, medical history in relation to respiratory symp-
toms is gained by a physician [42]. The quality of life in
children is measured by parent administered general
health related quality of life (FSII) questionnaires.
Samples size calculations
In a population of infants with recurrent asthma-like
symptoms, the prevalence of asthma at 6 years is known
to be 30% [1]. In this study, this results in at least 50 asth-
matic children given the 200 children with recurrent res-
piratory symptoms aged 2–3 years at the start, and a 10%
drop-out rate. The standard error of the sensitivity given a
chance on a positive test result of 0.8 will be 4.0%. The
standard error of the specificity with 150 children without
disease will be 3.0% given a chance on a positive test
result of 0.8. If the positive predictive value of the test is
0.7 and the negative predictive value 0.2 in a population
of N = 200, the statistical power for the relation between
the test and the definite diagnosis of asthma is 98%.
Data collection
The collected data are checked and cleaned by the centre
for data and information management of Maastricht Uni-
versity (MEMIC). All data are stored in a database at
MEMIC.
Data analysis
The data are analysed using quantitative statistics. Nor-
mally distributed data are expressed as mean and standard
error. Not normally distributed data are expressed as
median with interquartile ranges. Different analysis is per-
formed concerning the primary research question and sec-
ondary research questions.
Statistics of the primary research question
The primary research question is whether non-invasive
inflammatory biomarkers in exhaled breath and lungBMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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function indices can reliably predict asthma at an early
age. For this purpose, biomarkers collected in the experi-
mental group during the early diagnosis phase are used.
These parameters are related to the definite diagnosis of
asthma by means of multiple logistic regression analysis,
and discriminant analysis. Receiver Operating Character-
istic (ROC) curves and area under the curves (AUC) are
calculated.
Statistics of the secondary research questions
To answer the second research questions, data from both
experimental group and control group are used. Differ-
ences in parameters between the three groups (asthma,
'transient wheezers', and controls) are tested with analysis
of variance (one-way ANOVA or Kruskal-Wallis test in
case of parametric and non-parametric data, respectively).
For normally distributed data, Student's t-tests are used
for further analysis. Mann-Whitney U tests are used to test
for differences among non-parametric data. Differences
are defined as significant when p < 0.05.
Ethics
Ethical approval is obtained from the Dutch National
Medical Ethical Committee (CCMO). All parents gave
written informed consent. At the end of the study all par-
ents are informed about the personal primary outcome
measure (asthma diagnosis) of their child, and general
results of the study. The study protocol is extensively stud-
ied by the funding organizations: the Dutch Asthma
Foundation, Stichting Astma Bestrijding, and Maastricht
University Medical Centre. This study is registered by clin-
icaltrial.gov (NCT 00422747).
Discussion
We presented the protocol of the ADEM study that aims at
an early asthma diagnosis in young children using non-
invasive biomarkers of airway inflammation and early
lung function measurements. The design of the study is a
prospective, case-control study in 200 children with recur-
rent respiratory symptoms and 50 control subjects with
no respiratory symptoms. Our primary hypothesis is that
an early asthma diagnosis is possible using non-invasive
measurements of inflammatory biomarkers in exhaled
breath (condensate), and lung function tests. Besides,
aetiological factors including gene polymorphisms, gene
expression profiles, Treg cells and microbial colonisation
of airways and intestines are studied in relation to the
development of asthma.
The development of a new diagnostic tool for asthma at
an early age, based on non-invasive inflammatory
biomarkers in exhaled breath, and lung function can lead
to an early asthma diagnosis. This will result in better
treatment and probable a better prognosis of asthma in
children. Moreover, exclusion of asthma at an early age
prevents over-treatment in the children with transient
wheezing, which will reduce possible side effects and eco-
nomic costs. The design and setting of the ADEM study is
ideally suited to study the relation between different
parameters that are measured in early life, and the suscep-
tibility for asthma. This will increase insight in, for exam-
ple, the relation between the genetic background and the
pathophysiology of asthma in young children.
There are several critical success factors to be mentioned.
The study performs measurements in children aged 2–6
years old. Although the measurements are not invasive,
the question arises whether the measurements are feasible
in these young children. In a previous study in 70 pre-
school children, we established a success rate of EBC
measurements of 83% using the same condenser [19].
With respect to early lung functions measurements,
Merkus et al. found a feasibility of 88% of MicroRint
measurements in children aged 2 years and over [22]. We
hope to achieve success rates of the measurements of at
least 90% taken into account the non-invasive character of
the measurements, and our experience and learning curve
in the field of measurements of exhaled breath (conden-
sate) and lung function tests in children [19,35].
A trial with ICS is part of the diagnosis phase for the chil-
dren in the experimental group. A trial period with ICS is
often advocated but the precise diagnostic value is not
clear from earlier studies [25]. The children in the experi-
mental group consist of children who experienced at least
2–3 episodes of wheeze during their life. This can imply
that some children are symptom free at the start of the ICS
trial. Therefore, we expect a lower compliance in the
group children without current respiratory symptoms.
Compliance will be measured by weighting the ICS inha-
lators before and after the trial.
Children in this study are followed up for 3–4 years. This
long-term study can induce lost to follow-up, which is
dependent on compliance and the involvement of the
parents with the study. In our power analysis we calcu-
lated a lost to follow-up of 10%. Other studies of our
research group with a comparable design had a similar
drop-out rate [43].
The field of asthma genetics is evolving rapidly and genes
involved in asthma are discovered on a regular basis.
Therefore, selection of genes in this study is an ongoing
process and genes may be added if found relevant in the
literature.
In this study various parameters are measured. Because of
the large number of parameters that are measured, it is
important to distinguish the primary outcome measureBMC Public Health 2009, 9:210 http://www.biomedcentral.com/1471-2458/9/210
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from the aetiological factors that are studied. The results
of the aetiological part of this study have a more exploring
character and should be tested more extensively in future
research.
Conclusion
As an early diagnosis of asthma is currently difficult, both
under-diagnosis and under-treatment of asthmatic chil-
dren as well as over-treatment of transient wheezers occur
frequently. So far, assessments of inflammatory biomark-
ers play a minor role in the diagnosis of asthma. The
development of a new diagnostic tool for asthma at an
early age, based on non-invasive inflammatory biomark-
ers in exhaled breath and early lung function measure-
ments is a promising technique. These new diagnostic
techniques are applied in this study and probably make
an early diagnosis of asthma possible. This will result in
earlier and better treatment of childhood asthma.
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